AR030874A1 - Ester isopropilico de acido (2s)-2-(adamantan-1-ilmetoxicarbonilamino)-3-(4-(2-(1,4,5,6-tetrahidropirimidin-2-ilcarbamoil)etil)benzoilamino)propionico, su preparacion y su uso - Google Patents

Ester isopropilico de acido (2s)-2-(adamantan-1-ilmetoxicarbonilamino)-3-(4-(2-(1,4,5,6-tetrahidropirimidin-2-ilcarbamoil)etil)benzoilamino)propionico, su preparacion y su uso

Info

Publication number
AR030874A1
AR030874A1 ARP010104757A ARP010104757A AR030874A1 AR 030874 A1 AR030874 A1 AR 030874A1 AR P010104757 A ARP010104757 A AR P010104757A AR P010104757 A ARP010104757 A AR P010104757A AR 030874 A1 AR030874 A1 AR 030874A1
Authority
AR
Argentina
Prior art keywords
adamantan
propionic
preparation
ester
tetrahydropirimidin
Prior art date
Application number
ARP010104757A
Other languages
English (en)
Original Assignee
Aventis Pharma Gmbh
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh, Genentech Inc filed Critical Aventis Pharma Gmbh
Publication of AR030874A1 publication Critical patent/AR030874A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
    • C07D239/12—Nitrogen atoms not forming part of a nitro radical
    • C07D239/16—Nitrogen atoms not forming part of a nitro radical acylated on said nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invencion se refiere al éster isopropílico de ácido (2S)-2-(adamantan-1-ilmetoxicarbonilamino)-3-(4(2-(1,4,5,6-tetrahidropirimidin-2-ilcarbamoil)etil)-benzoilamino)propionico de formula (1) y a sus sales fisiologicamente tolerables, a su preparacion, a su uso como agentes farmacéuticos y a composiciones farmacéuticas que los comprenden. El compuesto de formula I y a sus sales fisiologicamente tolerables son valiosos compuestos farmacologicamente activos que pueden ser empleados, por ejemplo, en el tratamiento o profilaxis de enfermedades que pueden ser influidas inhibiendo el receptor de vitronectina, por ejemplo enfermedades oseas tales como la osteoporosis.
ARP010104757A 2000-10-10 2001-10-10 Ester isopropilico de acido (2s)-2-(adamantan-1-ilmetoxicarbonilamino)-3-(4-(2-(1,4,5,6-tetrahidropirimidin-2-ilcarbamoil)etil)benzoilamino)propionico, su preparacion y su uso AR030874A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00121986A EP1197488A1 (en) 2000-10-10 2000-10-10 (2S)-2-(Adamantan-1-ylmethoxycarbonylamino)-3-(4-(2-(1,4,5,6-tetrahydropyrimidin-2-ylcarbamoyl)ethyl)benzoylamino)propionic acid isopropyl ester, its preparation and its use

Publications (1)

Publication Number Publication Date
AR030874A1 true AR030874A1 (es) 2003-09-03

Family

ID=8170045

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010104757A AR030874A1 (es) 2000-10-10 2001-10-10 Ester isopropilico de acido (2s)-2-(adamantan-1-ilmetoxicarbonilamino)-3-(4-(2-(1,4,5,6-tetrahidropirimidin-2-ilcarbamoil)etil)benzoilamino)propionico, su preparacion y su uso

Country Status (8)

Country Link
US (1) US6867213B2 (es)
EP (2) EP1197488A1 (es)
JP (1) JP2004511472A (es)
AR (1) AR030874A1 (es)
AT (1) ATE466844T1 (es)
AU (1) AU2002220571A1 (es)
DE (1) DE60142063D1 (es)
WO (1) WO2002030910A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0327527D0 (en) * 2003-11-26 2003-12-31 Univ Bern Organic compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19629816A1 (de) * 1996-07-24 1998-01-29 Hoechst Ag Neue Cycloalkyl-Derivate als Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten
EP0933367A1 (en) * 1997-12-19 1999-08-04 Hoechst Marion Roussel Deutschland GmbH Novel acylguanidine derivates as inhibitors of bone resorption and as vitronectin receptor antagonists

Also Published As

Publication number Publication date
EP1326847A1 (en) 2003-07-16
US20040039006A1 (en) 2004-02-26
AU2002220571A1 (en) 2002-04-22
ATE466844T1 (de) 2010-05-15
US6867213B2 (en) 2005-03-15
JP2004511472A (ja) 2004-04-15
EP1326847B1 (en) 2010-05-05
WO2002030910A1 (en) 2002-04-18
DE60142063D1 (de) 2010-06-17
EP1197488A1 (en) 2002-04-17

Similar Documents

Publication Publication Date Title
SV2004001413A (es) Sales de acido succinico de 5,7,14-triazatetraciclo[10.3.1.2,11.04,9]-hexadeca-2(11),3,5,7,9-pentaeno y composiciones farmaceuticas de las mismas ref.pc23247
EA200000682A1 (ru) Новые ацилгуанидиновые производные в качестве ингибиторов резорбции костной ткани и антагонистов витронектиновых рецепторов
UY29825A1 (es) Derivados sustituidos de 3h-imidazol-(4,5 b (beta))piridina-2-il benzoatos y benzamidas, composiciones farmacéuticas que los contienen y aplicaciones
BR9916790A (pt) Uso de um composto, composto, processo para amanufatura do mesmo, composição farmacêtica, e,método para produzir um efeito de dano vascularem um animal de sangue quente
UY26872A1 (es) Derivados de la 4- fenil piridina
AR029857A1 (es) Derivados de acidos sulfonil-amino-metil-benzoicos sustituidos y procedimiento para su preparacion
BR0317294A (pt) Composto, formulação farmacêutica, uso de um composto, métodos de prevenção e/ou tratamento de condições associadas com a glicogênio sintase quinase-3 e de prevenção e/ou tratamento de doenças, e, uso dos intermediários
GT200100137A (es) Pro-drogas de derivados de 4-fenil-piridina.
IL149150A0 (en) 2-(4-(6-methoxy-naphthalene-2-yl)-5-pyridin-4-yl-1h-imidazole-2-yl)-2-methyl-derivatives, pharmaceutical compositions comprising them and use thereof as tie2 receptor kinase inhibitors
PE20060589A1 (es) FENILAMINOTIAZOLES SUSTITUIDOS COMO AGONISTAS DE ADENOSINA A1 Y A2b
UY30274A1 (es) Derivados sustituidos de la n-(4-metil-1,3-tiazol-2-il)guanidina, formulaciones farmacéuticas conteniéndolo y aplicaciones
PA8494101A1 (es) Derivados heterociclicos utiles como agentes anticancerosos
NO20044041L (no) Okso-azabisykliske forbindelser
BG104630A (en) Novel sulfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesion
GT200000197A (es) 2-(3,5-bis-trifluorometil-fenil)-n-metil-n-(6- morfolin-4-il-4-o tolil-piridin-3-il)-isobutiramida.
BR0309028A (pt) Compostos policìclicos como antagonistas potentes de alfa2-adrenoceptores
ATE273285T1 (de) Neue guanidin-derivate als zelladhäsion- inhibitoren
AR005827A1 (es) Compuesto derivado de nucleosidos aciclicos, composicion farmaceutica que lo comprende, uso del mismo en la preparacion de un medicamento y su metodo de preparacion
BRPI0519152A2 (pt) composto ou um sal ou derivado Éster farmaceuticamente aceitÁvel do mesmo, formulaÇço farmacÊutica, formulaÇÕes para tratar osteoporose e psorÍase, uso de um composto ou de um sal farmaceuticamente aceitÁvel do mesmo, e, composiÇço farmacÊutica
NO20060277L (no) Anvendelse av bisyklo [2.2.1] heptanderivater til fremstilling av nevrobeskyttende farmasoytiske sammensetninger
CO5590934A2 (es) Procedimiento de preparacion de derivados de equinocandina
AR048716A1 (es) Derivados de acido pentenoico, procedimientos para su preparacion, composiciones farmaceuticas que los comprenden y sus aplicaciones terapeuticas
AR030874A1 (es) Ester isopropilico de acido (2s)-2-(adamantan-1-ilmetoxicarbonilamino)-3-(4-(2-(1,4,5,6-tetrahidropirimidin-2-ilcarbamoil)etil)benzoilamino)propionico, su preparacion y su uso
DK1179342T3 (da) Medicinske sammensætninger til öjeblikkelig frigivelse ved oral anvendelse
HUP0004701A2 (hu) Új dezloratadin sók, az ezeket tartalmazó gyógyászati készítmények és eljárás azok előállítására

Legal Events

Date Code Title Description
FB Suspension of granting procedure